Lifecare advances rapidly towards repeatable in-house implant manufacturing at new Bergen facilities

Nine implants that successfully completed pressure and electronic qualification testing in Bergen were shipped to Lifecare’s Bristol operations on 20 October for end-of-line testing.

A further production batch was completed on 24 October, with eight implants successfully completing the applicable qualification testing in Bergen.

The latest production activity follows Lifecare’s announcement on 29 September 2026 of the first successful in-house production of functional CGM implants in Bergen. That initial batch consisted of three implants, of which two successfully completed testing.

Within less than one month, Lifecare has progressed from its first three-units produced in Bergen to successive production runs yielding a total of 19 implants successfully completing qualification testing.

“We are seeing a solid and rapid development in our manufacturing capability. Less than a month ago, we communicated the first functional implants manufactured in Bergen. Since then, we have moved into substantially larger and successive production runs,” says Joacim Holter, CEO of Lifecare.

“We are establishing the capability for a repeatable production rhythm and demonstrating that the manufacturing process can be repeated across successive batches at materially higher volumes.”

The first functional implants communicated 29 September were produced on Lifecare’s temporary production line in Bergen. The subsequent production batches have been manufactured at the Company’s new facilities following the acquisition of Ocean Tunicell AS. The new facilities bring together dedicated production and laboratory infrastructure, increased space and technical personnel, and have enabled a more efficient manufacturing workflow and higher production volumes.

Final operational step in consolidating implant manufacturing in Bergen

Lifecare is now preparing to transfer end-of-line testing from Bristol to Bergen, representing the final major operational step in consolidating the implant manufacturing workflow at the Company’s Bergen facilities.

End-of-line testing was initially established at Lifecare’s specialised chemistry laboratories in Bristol. The new Bergen facilities now provide the laboratory infrastructure, production environment and personnel required to centralise this function alongside implant manufacturing.

Personnel from Bristol will support the transfer and establishment of end-of-line testing in Bergen. Implants from the latest production batch are therefore intended to undergo end-of-line testing in Bergen rather than being shipped to Bristol.

At the same time, Lifecare has increased staffing at Lifecare Chemistry in Bristol to expand laboratory throughput and development capacity. With end-of-line testing moving to Bergen, the Bristol team will increasingly focus on chemistry development, including further product optimisation for glucose sensitivity and continued development of Lifecare’s osmotic sensing technology.

“Moving end-of-line testing to Bergen allows us to sharpen the role of both sites. Bergen is becoming our centre for implant manufacturing and testing, while Bristol can focus more fully on chemistry innovation,” Holter says.

“The increased capacity at Lifecare Chemistry is intended both to accelerate optimisation of our glucose sensing chemistry and to give us greater capacity to investigate the broader platform potential of our sensing technology.”

Glucose remains Lifecare’s primary development focus, while the Company continues to evaluate the potential of its osmotic sensing principle as a platform for additional analytes.

Lifecare does not intend to provide market updates on individual production batches going forward. The current development is considered relevant as the successive production runs, consolidation of manufacturing and testing in Bergen, and increased development capacity in Bristol demonstrate material progression in both manufacturing capability and technology development.